Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
earnings
Rhea-AI Summary
Rockwell Medical, Inc. (RMTI) will release its first quarter 2024 financial and operational results on May 14, 2024. The Company develops, manufactures, and distributes hemodialysis products globally. A live conference call and webcast will follow the press release.
Positive
- None.
Negative
- None.
CONFERENCE CALL AND WEBCAST DETAILS
Date: Tuesday, May 14, 2024
Time: 8:00am ET
Live Number: (888) 660-6347 // (International) 1 (929) 201-6594
Conference Call ID: 4944610
Webcast and Replay: www.RockwellMed.com/Results
Format: Discussion of first quarter 2024 financial and operational results followed by Q&A.
ABOUT ROCKWELL MEDICAL
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed at freestanding outpatient dialysis centers, at hospital-based outpatient centers, at skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Rockwell Medical is the largest supplier of liquid bicarbonate concentrates and the second largest supplier of acid and dry bicarbonate concentrates for dialysis patients in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416211272/en/
Heather R. Hunter
SVP, Chief Corporate Affairs Officer
(248) 432-1362
IR@RockwellMed.com
Source: Rockwell Medical, Inc.
Rockwell Medical will release its first quarter 2024 financial and operational results on Tuesday, May 14, 2024.
Rockwell Medical develops, manufactures, and distributes a portfolio of hemodialysis products to dialysis providers worldwide.
The live conference call and webcast will take place at 8:00am ET on Tuesday, May 14, 2024.
You can access the webcast and replay of the first quarter 2024 results on www.RockwellMed.com/Results.
Rockwell Medical Inc
NASDAQ:RMTI
RMTI Rankings
N/A Ranked by Market Cap
#245 Ranked by Stock Gains
N/A Ranked by Dividends
RMTI Latest News
Apr 4, 2024
Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda
Mar 25, 2024
Rockwell Medical Named 'Great Place to Work' for Second Year in a Row
Mar 21, 2024
Rockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023
Feb 8, 2024
Rockwell Medical to Release Fourth Quarter and Full-Year 2023 Results on Thursday, March 21, 2024
Jan 8, 2024
Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund
RMTI Stock Data
Surgical and Medical Instrument Manufacturing
Manufacturing
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Wixom
About RMTI
rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www
